TradeOrgs
  • 🇮🇳 India
  • 🇺🇸 US
  • Screener
  • Backtest
  • Watchlist
  • Signals
  • Portfolio
  • Insights
  • Connect
Sign in
RELIANCE₹1,377.50▲ 14.60%TCS₹2,376.20▼ 3.44%HDFCBANK₹846.00▲ 18.82%ICICIBANK₹1,640.00▲ 18.75%INFY₹1,098.00▼ 2.89%HINDUNILVR₹2,052.50▲ 10.75%ITC₹299.10▲ 14.69%SBIN₹1,165.10▲ 19.66%BHARTIARTL₹2,161.70▲ 15.28%KOTAKBANK₹515.80▲ 16.62%LT₹4,209.10▲ 14.94%AXISBANK₹1,446.00▲ 16.99%ASIANPAINT₹2,608.30▲ 11.91%MARUTI₹14,011.00▲ 22.10%AAPL$342.56▲ 0.90%MSFT$484.52▼ 8.90%GOOGL$265.29▼ 22.04%AMZN$246.82▼ 6.02%NVDA$125.53▼ 42.01%META$560.84▼ 19.22%TSLA$345.82▼ 7.46%BRK-B$570.00▲ 5.59%JPM$310.53▼ 7.38%V$401.87▼ 1.16%
RELIANCE₹1,377.50▲ 14.60%TCS₹2,376.20▼ 3.44%HDFCBANK₹846.00▲ 18.82%ICICIBANK₹1,640.00▲ 18.75%INFY₹1,098.00▼ 2.89%HINDUNILVR₹2,052.50▲ 10.75%ITC₹299.10▲ 14.69%SBIN₹1,165.10▲ 19.66%BHARTIARTL₹2,161.70▲ 15.28%KOTAKBANK₹515.80▲ 16.62%LT₹4,209.10▲ 14.94%AXISBANK₹1,446.00▲ 16.99%ASIANPAINT₹2,608.30▲ 11.91%MARUTI₹14,011.00▲ 22.10%AAPL$342.56▲ 0.90%MSFT$484.52▼ 8.90%GOOGL$265.29▼ 22.04%AMZN$246.82▼ 6.02%NVDA$125.53▼ 42.01%META$560.84▼ 19.22%TSLA$345.82▼ 7.46%BRK-B$570.00▲ 5.59%JPM$310.53▼ 7.38%V$401.87▼ 1.16%

TradeOrgs shows market information and analyzes your own trading history. It does not place trades and is not investment advice.

Prices and listings are for information only. We are read-only against your broker account.

Technical signals (RSI, MACD, etc.) are educational readouts of public indicators — not recommendations.

Privacy Policy·© 2026 TradeOrgs

← US stocks

🇺🇸AMRX

Amneal Pharmaceuticals, Inc. - Class A Common Stock

NASDAQ
$21.12
▲ $1.94 (+10.1%)
Live· just now
delayed feed · not for order timing

Price history · 20-day (cyan) / 50-day (purple) avg

as of 17 Nov 2026
H $22.07L $11.76+67.6%
$22.07$20$17.94$15.88$13.82$11.76$21.12
RSI (14)
Intraday · 15-minBuy+20RSI 55SidewaysMACD Bullishfor day-trading context — not advice

Technical signal

Strong buy+60
RSI (14)56
oversold 30overbought 70
Trend
Uptrend
MACD
Bullish
Bollinger
Within bands
vs 20-day
above
vs 50-day
above
vs 200-day
above
Support
$19.01
Resistance
$22.07
  • Price is above its 50-day average (medium-term uptrend).
  • Price is above its 200-day average (long-term uptrend).

Signal backtest · 2026-02-17 → 2026-11-17

Strategy return
+21.7%
Buy & hold
+39.0%
Trades
6
Win rate
33%

$100,000.00 invested would be worth $121,740.64 (+21.7%) · Full backtester →

Hypothetical: go long when the signal turns Buy, exit when it turns Sell. Past indicator behavior is not a prediction — educational only, not advice.

About Amneal Pharmaceuticals, Inc.· Drug Manufacturers - Specialty & Generic

source: yahoo

Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally. The company operates through three segments: Affordable Medicines, Specialty, and AvKARE. The Affordable Medicines segment offers dosage forms and delivery systems, which include immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, transdermal patches, and topicals. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with a focus on central nervous system and endocrine disorders, including Parkinson's disease. This segment provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid and ONGENTYS for the treatment of hypothyroidism; and CREXONT, which is use for the treatment of Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, retail pharmacies, managed care organizations, purchasing co-ops, hospitals, government agencies, institutions, and pharmaceutical companies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
8,700
Headquarters

Fundamentals

source: yahoo
Market cap
$7.36B
P/E
52.8
P/B
13.8
EPS
$0.40
Div yield
0.0%
Profit margin
4.2%
ROE
70.0%
Debt / Equity
5.12
Beta
1.21
52-week range
$11.71 – $22.13
52-week low · $11.7190% of rangehigh · $22.13

Fundamental data is informational only — not investment advice.

Recent news

News sentiment:▲ Positive5↑ · 3↓ · 0–
  • Amneal Announces European Approval of Adcomfo® (Omalizumab), a Biosimilar to XOLAIR®▲ Positive
    GlobeNewswire · 17 Nov 2026
  • 3 Insider Backed Growth Stocks With At Least 40% Earnings Growth▲ Positive
    Simply Wall St. · 17 Nov 2026
  • Xenon Stock Rises 12% in the Past Month on Pipeline Progress▲ Positive
    Zacks · 17 Nov 2026
  • Summit Stock Falls on FDA Rejection for Lung Cancer Drug

Educational technical indicators — not investment advice. TradeOrgs does not place trades.

Bridgewater, United States
www.amneal.com ↗
▼ Negative
Zacks · 16 Nov 2026
  • QURE Stock Rallies 17.5% in a Month: What Should Investors Do Now?▲ Positive
    Zacks · 13 Nov 2026
  • Kodiak Q3 Loss Wider Than Expected, Pipeline Development in Focus▼ Negative
    Zacks · 13 Nov 2026
  • Sentiment is a keyword-based read of the headline — a rough signal, not advice.